The FDA has also indicated that the sNDA will receive priority review in accordance with the Best Pharmaceuticals for Children Act, which provides for a 180-day review period. Aciphex was discovered and developed by Eisai and is co-promoted in the US with PriCara, a division of Ortho-McNeil-Janssen Pharmaceuticals.